Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

Also called NCT06763744

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06763744
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06763744. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
Acronym
GUIDE-HBR
Condition
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI (percutaneous coronary intervention))
Condition
High Bleeding Risk
Intervention (Drug)
P2Y12 antagonist monotherapy
Intervention (Drug)
clopidogrel + aspirin
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct06763744
Content hash
ed39e45cac120a9c79c14b5956a75ca50fa29d41263f37f51d81374d9a85b770